2C-T-15
| Clinical data | |
|---|---|
| Other names | 4-Cyclopropylthio-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-cyclopropylthiophenethylamine; SESQUI |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | "Several hours"[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H19NO2S |
| Molar mass | 253.36 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 203.5 to 204.5 °C (398.3 to 400.1 °F) |
| |
| |
| | |
2C-T-15, also known as 4-cyclopropylthio-2,5-dimethoxyphenethylamine, is a psychedelic phenethylamine of the 2C family.[1] It was presumably first synthesized by Alexander Shulgin and reported in his book PiHKAL (Phenethylamines i Have Known And Loved).[1]
Use and effects
[edit]The dose range of 2C-T-15 is typically 30 mg or more. Its duration is unspecified by Shulgin, and its entry in PiHKAL says it lasts for "several hours."[1] The effects are not prominent, and 2C-T-15 is not very potent.
Toxicity
[edit]The toxicity of 2C-T-15 is not well documented. 2C-T-15 is much less potent than 2C-T-7, but it may be expected that at very high doses it would display similar toxicity to that of other phenethylamines of the 2C-T family.[citation needed]
Interactions
[edit]Pharmacology
[edit]Pharmacodynamics
[edit]The mechanism that produces 2C-T-15's hallucinogenic and entheogenic effects has not been specifically established; however, it is most likely to result from action as a 5-HT2A serotonin receptor agonist in the brain, a mechanism of action shared by all of the hallucinogenic tryptamines and phenethylamines for which the mechanism of action is known.[citation needed]
Chemistry
[edit]2C-T-15 is the 2 carbon homologue of Aleph-15, which has not been synthesized.[1] The full chemical name is 2-[4-(2-cyclopropylthio)-2,5-dimethoxyphenyl]ethanamine.[1] The drug has structural properties similar to 2C-T-2 and other drugs in the 2C-T series.[1]
History
[edit]2C-T-15 was first described in the scientific literature by Alexander Shulgin and colleagues in 1991.[2]
Society and culture
[edit]Legal status
[edit]Canada
[edit]As of October 31, 2016, 2C-T-15 is a controlled substance (Schedule III) in Canada.[3]
United Kingdom
[edit]2C-T-15 is a class A drug in the UK under the Misuse of Drugs act.
United States
[edit]2C-T-15 is not explicitly illegal in the USA, but possession and sales of 2C-T-15 could be prosecuted under the Federal Analog Act because of its structural similarities to 2C-T-7.
See also
[edit]References
[edit]- ^ a b c d e f g h Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
- ^ Shulgin AT, Shulgin A, Jacob P (January 1991). "Central nervous system (CNS) activity of two new psychoactive compounds". Journal of Psychoactive Drugs. 23 (1): 95–96. doi:10.1080/02791072.1991.10472583. eISSN 2159-9777. PMID 1941371. Archived from the original on 2025-07-13.
- ^ "Canada Gazette – Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". 4 May 2016.